What the UK cohort measured
Researchers used UK primary care records from 2007 to 2023. They identified 47,315 adults starting a GLP-1 receptor agonist and 159,066 starting a DPP-4 inhibitor. Everyone had type 2 diabetes and a BMI of at least 30 and had no prior recorded sleep apnea diagnosis. The researchers weighted the groups within BMI categories to balance measured baseline characteristics and used an as-treated analysis with up to three years of follow-up[1].
There were 612 new diagnoses in the GLP-1 group and 1,197 in the DPP-4 inhibitor group. The incidence rates were 5.8 and 5.4 per 1,000 person-years, respectively. The confidence interval around the hazard ratio of 1.07 included both a lower and a higher diagnosis rate. Results were consistent across BMI groups, sex, drug type and sensitivity analyses [1].
How this differs from the treatment trials
The SURMOUNT-OSA tirzepatide trials used sleep studies to measure breathing events among adults with obesity who already had moderate-to-severe obstructive sleep apnea. Tirzepatide reduced events compared with placebo in both trials [2]. The U.S. FDA indication is for Zepbound in adults with obesity and moderate-to-severe obstructive sleep apnea [3].
A clinical diagnosis in primary care can depend on who is referred and tested. It does not tell researchers exactly when apnea began. The survey of sleep-clinic follow-up practices covers a separate example of how follow-up can vary after treatment and weight loss. The UK cohort compared prescriptions in routine care, so it could not isolate the effect of weight loss itself.